logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9827331 B1

PDFFull Text
Date of Patent:
Nov. 28, 2017

Filed:

Sep. 25, 2015

Nucleic acid-lipopolymer compositions

Applicant:

Clsn Laboratories, Inc., Wilmington, DE (US);

Inventors:

Majed Matar, Madison, AL (US);

Jason Fewell, Madison, AL (US);

Danny H. Lewis, Hartselle, AL (US);

Khursheed Anwer, Madison, AL (US);

Assignee:

CLSN Laboratories, Inc., Wlimington, DE (US);

Attorneys:

Sterne, Kessler, Goldstein & Fox

Eric Steffe

Bonnie Nannenga-Combs

Primary Examiner:

Robert M Kelly

Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 38/20 (2006.01); A61K 47/48 (2006.01); A61K 9/19 (2006.01); C12N 15/113 (2010.01); C12N 5/00 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 31/70 (2006.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01); A61K 47/38 (2006.01); C12N 15/11 (2006.01); C12N 15/88 (2006.01); A61K 47/60 (2017.01); A61K 47/54 (2017.01); A61K 47/59 (2017.01); A61K 47/64 (2017.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0041 (2013.01); A61K 9/0019 (2013.01); A61K 9/1272 (2013.01); A61K 9/19 (2013.01); A61K 31/70 (2013.01); A61K 38/208 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01); A61K 47/554 (2017.08); A61K 47/59 (2017.08); A61K 47/60 (2017.08); A61K 47/6455 (2017.08); A61K 48/0075 (2013.01); C12N 5/00 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 15/88 (2013.01); A61K 38/00 (2013.01); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01); C12N 2510/00 (2013.01);
Abstract

Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.

Find Patent Forward Citations

Loading…